Quantcast
Last updated on April 18, 2014 at 15:11 EDT

Latest Bevacizumab Stories

2012-09-06 02:32:41

INDIANAPOLIS, Sept. 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of ALIMTA(®) (pemetrexed for injection) with bevacizumab (AVASTIN(®)) and carboplatin induction followed by ALIMTA plus bevacizumab maintenance-the ALIMTA arm-compared to the combination...

2012-09-06 02:30:59

INCLINE VILLAGE, Nev., Sept. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the third quarter ending September 30, 2012, of approximately $85 million, as compared with actual royalty revenue of $83 million for the third quarter of 2011, a two percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in royalty revenues is driven by increased second quarter 2012 sales of...

2012-08-20 23:00:57

On August 13th, Atlanta LASIK surgeon Dr. Ashraf released findings about the drug Lucentis, approved by the FDA and used to treat eye conditions like Diabetic Macular Edema. Atlanta, GA (PRWEB) August 20, 2012 On August 13th, Dr. Ashraf of the Atlanta Vision Institute released information about a study that was performed using Lucentis, a drug approved by the FDA that treats Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). AMD is an eye condition that is common among...

2012-08-16 02:24:19

CALGARY, Aug. 16, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.S. Phase I clinical trial using REOLYSIN in combination with FOLFIRI (Folinic Acid (leucovorin) with Fluorouracil (5-FU) and Irinotecan) in patients with oxaliplatin refractory, Kras mutant colorectal cancer (REO 022). The trial is a 21-patient, single arm dose escalation study designed to determine a maximum tolerated...

2012-08-07 02:29:36

SAN FRANCISCO, Aug. 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today the start of a Phase 2 study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at Stanford Cancer Institute. The Phase 2 study is an investigator-sponsored trial being conducted under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigators Seema Nagpal, M.D. and Pamela Kunz, M.D. "Patients with...

2012-08-03 10:21:33

PARIS and TARRYTOWN, N.Y., Aug. 3, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP(®) (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen....

2012-07-08 22:21:18

GREENWOOD VILLAGE, Colo., July 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion(TM) , Optina(TM) & Zertane(TM)), announced the significant results from their further analysis of its Optina(TM) trial on DME . (Logo:...

2012-07-02 02:24:33

CAMBRIDGE, Mass., July 2, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin®, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer. (Logo:...

2012-06-26 14:21:22

MELBOURNE, Australia, June 26, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that it has been advised by its development partner, Healthscope Advanced Pathology, that it will commercially launch Circadian's novel technology for aid in the diagnosis of "Cancers of Unknown Primary" (CUP), on Monday July 16 2012 in Australia, New Zealand, Singapore and Malaysia under the brand CUPGUIDE(TM). The diagnostic test method has been developed in collaboration...

2012-06-18 10:23:57

KINGSTON, ON, June 18, 2012 /PRNewswire/ - At the center of the debate of how to potentially save the healthcare system millions of dollars are two drugs used to treat wet age-related macular degeneration (AMD), the leading cause of blindness in seniors. One, Lucentis, is FDA and Health Canada-approved and costs $1,700.  The other, Avastin, is used off-label and costs one-tenth the price. Eye doctors currently use both drugs to treat AMD and some studies have shown that they...